Amgen today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall ...

UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the presentation of the uTRACT Registry ...

We are pleased to share the May 2025 issue of Wilson Sonsini’s Sustainability and ESG Advisory Practice Update. Each issue combines news, key ...